Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript

Eli Lilly (LLY) convened a special investor event on June 22, 2025, during the American Diabetes Association's 85th Scientific Sessions, to detail its cardiometabolic health strategy and pipeline. Key executives, including Ken Custer and Dr. Jeff Emmick, presented updates, specifically highlighting recently presented orforglipron data from the ACHIEVE-1 study. This event provides institutional investors with direct insights into Lilly's focus on its high-growth cardiometabolic franchise and the progress of a significant pipeline asset.

Analysis

Eli Lilly (LLY) hosted a targeted investor event at the American Diabetes Association's 85th Scientific Sessions, signaling a strategic effort to communicate directly with key market participants. The agenda centered on the company's cardiometabolic health strategy, a critical growth driver, with senior leadership including the President of Cardiometabolic Health presenting. A key focus of the event was the disclosure and discussion of new data for orforglipron from the ACHIEVE-1 study, a significant asset in Lilly's pipeline. The presence of numerous sell-side analysts from top-tier firms like Morgan Stanley, Citigroup, and Jefferies, alongside a major institutional investor like T. Rowe Price, underscores the high level of investor interest in Lilly's pipeline and its potential to further solidify its leadership in the diabetes and obesity markets. The event's primary function is to allow management to frame the narrative around this new data and reinforce its long-term strategy for this highly competitive therapeutic area.

Key Decisions for Investors

• Investors should closely monitor the detailed orforglipron data from the ACHIEVE-1 study and the subsequent analyst reports, as these will be primary drivers of near-term sentiment and valuation adjustments for LLY.
• Pay close attention to management's qualitative commentary during the Q&A portion of the event, as their framing of the data's competitive standing and market potential will provide crucial insight beyond the clinical results.
• The event serves as a catalyst; positions should be evaluated based on the substance of the new data and whether it reinforces or alters the long-term growth thesis for Lilly's cardiometabolic franchise.